Extracellular Matrix in Synthetic Hydrogel‐Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors (Adv. Mater. 2/2022). Issue 2 (13th January 2022)

• Record Type: Journal Article
• Authors: Mosquera, Matthew J.; Kim, Sungwoong; Bareja, Rohan; Fang, Zhou; Cai, Shuangyi; Pan, Heng; Asad, Muhammad; Martin, Maria Laura; Sigouros, Michael; Rowdo, Florencia M.; Ackermann, Sarah; Capuano, Jared; Bernheim, Jacob; Cheung, Cynthia; Doane, Ashley; Brady, Nicholas; Singh, Richa; Rickman, David S.; Prabhu, Varun; Allen, Joshua E.; Puca, Loredana; Coskun, Ahmet F.; Rubin, Mark A.; Beltran, Himisha; Mosquera, Juan Miguel; Elemento, Olivier; Singh, Ankur
• Is Part Of: Advanced materials. Volume 34:Issue 2(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-01-13
• Subjects: chemoresistance -- dopamine receptors -- epigenetics -- neuroendocrine -- tumor microenvironment; Materials -- Periodicals; Chemical vapor deposition -- Periodicals; 620.11
• DOI: 10.1002/adma.202270014
• Languages: English
• ISSNs: 0935-9648

Abstract

Abstract : Cancer Therapy In article number 2100096, Olivier Elemento, Ankur Singh, and co‐workers examine the prostate cancer tumor microenvironment using multi‐omics techniques and report a prostate cancer organoid bioengineered using a modular synthetic hydrogel that shapes the epigenetics and transcriptomics of cancer cells. They discover the "dopamine receptor" pathway as a targeted therapy for epigenetically reprogrammed neuroendocrine prostate cancers.